Loading…
← CockpitCompetitor Analysis › VETO.PA Vetoquinol SAOpen in the cockpit ↗

Vetoquinol SAVETO.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Major

French animal-health company making veterinary medicines and health products for pets and farm animals.

≈ A smaller French Zoetis/ElancoMomentum leader 97
Mkt cap
$1.10B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$757,697
20-day average traded
Fwd P/E
15.5×
forward earnings
ROIC−WACC
+7.1 pp
WACC 8.0%
Hurdle
-8 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · EUR€86.40
1D+0.2%
1W-1.5%
1M+8.0%
3M+22.6%
6M+18.7%
YTD+3.5%
1Y+19.5%
ATR %2.6%
52w lowhigh5.6% off high

What Vetoquinol does

French animal-health company making veterinary medicines and health products for pets and farm animals.

Sells animal medicines to veterinarians directly and through distributors, so growth follows vets' prescribing habits and product registrations in each country. The founding Vetoquinol family still controls the group.

In one line: A smaller French Zoetis/Elanco.

Products and services

  • Companion animal medicines
  • Farm animal/livestock health products
  • Diagnostics

Customers

  • Veterinarians
  • Farmers/livestock producers
  • Pet owners (via vets)

Where it sits in the supply chain

  • Health Care
  • Animal health
  • Veterinary pharmaceuticals

What could go right

  • Pet-ownership growth/pet health spending
  • Emerging-market veterinary demand

What could go wrong

  • Generic veterinary drug competition
  • Farm-sector livestock cycle downturns

Moat: narrow (regulatory licence, brand, distribution). Established veterinary product registrations and distribution in Europe, but small next to global animal-health leaders.

Headquarters: Lure, France · Founded: 1933 · Employees: 2,501

Named competitors

Vetoquinol at a glance

Size Vetoquinol (VETO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.10B, the 130th largest of 206 France companies the cockpit tracks. Shares closed at €86.40 on 18 Nov 2026.

Performance Over six months the shares gained 18.7%, against -7.1% for the median peer and -2.1% for the France market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 0.9% over the last twelve months (peer median -2.3%); the operating margin is 14.8% (peer median 5.4%).

Valuation It trades at 15.5× forward earnings against a peer median of 20.2× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.1 points above its cost of capital (8.0% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026VETO.PA 120Peer median 93
Six months, rebased to 100: Vetoquinol against the median of its 20 peers (local-currency closes).

Vetoquinol financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€527M€526M€539M€529M€540M
Revenue growth—-3%+2%-2%—
Gross profit€84.6M€160M€159M€158M€172M
EBITDA€110M€105M€102M€97.3M€111M
Net income€62.8M€57.4M€58.7M€55.6M€48.0M
Free cash flow€87.1M€59.0M€75.9M€76.2M€45.4M
Capital expenditure€18.6M€20.7M€17.7M€19.0M€22.5M
Total debtn/a€15.3M€21.1M€17.6M€17.4M

Quarterly statements and history in the cockpit →

Vetoquinol competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%300119237690VIYASHPYCMEDCL006280600812OMERCMHC45471952BLUEJET000989600789BSLN6855NKTRVETO.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Vetoquinol is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×300119237690VIYASH006280CMHC1952BLUEJET000989VETO.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vetoquinol is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300119237690VIYASH600812002550BLUEJET000989600789BSLNVETO.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vetoquinol is the large dot.

Vetoquinol competitors and peer comparison

Head to head with its named competitors (VETO.PA vs ZTS vs ELAN vs VIRP.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Vetoquinol VETO.PA$1.10B+19%-1%15%15.5×-3.6%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Virbac VIRP.PA$3.20B-4%+4%15%16.6×5.8%

How Vetoquinol compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vetoquinol against its 20 peers (data as of 18 Nov 2026)
MeasureVETO.PAPeer medianRank in peer set
1-month return+8.0%-2.0%3rd highest of 21
6-month return+18.7%-7.1%4th highest of 20
Distance from 52-week high-5.6%-32.1%2nd highest of 21
Revenue growth (TTM)-0.9%-2.3%8th highest of 17
Operating margin14.8%5.4%6th highest of 18
Forward P/E15.5×20.2×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)-3.6%3.4%3rd least demanding of 10
Growth delivered (Del g)+4.2%+11.3%4th lowest of 10
Hurdle (Req g minus delivered)-7.8 pp+4.6 pp3rd least demanding of 10
ROIC minus cost of capital+7.1 pp-2.8 pp4th highest of 18
EV / EBITDA7.1×14.1×cheapest of 7
Net debt / EBITDA-2.0×-1.3×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a

Questions

Who are Vetoquinol's main competitors?
Named competitors: Zoetis (ZTS), Elanco Animal Health (ELAN), Virbac (VIRP.PA). The cockpit's measured peer set (industry) also includes Tianjin Ringpu Bio-technology (300119.SZ), ST Pharm (237690.KS), Viyash Scientific (VIYASH.NS), PYC Therapeutics (PYC.AX), Symbiotec Pharmalab (SYMBIOTEC.NS), MedinCell (MEDCL.PA).
Is Vetoquinol expensive compared with its peers?
On forward p/e it trades at 15.5× against a peer median of 20.2×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Vetoquinol stock performed?
Over six months to 18 Nov 2026 the shares returned +18.7% against -7.1% for the median peer; over one year +19.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.